Sign In
Buy ATRA
$9.63
-0.270 (-2.73%)
At Close: Jun 03, 2026
Atara Biotherapeutics: Upcoming Catalysts And Validated Pipeline
10:00pm, Wednesday, 30'th Jun 2021
ATRA will have an approval next year in a rare disease. Its major deal with Bayer validates its earliest stage programs.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformati
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:01pm, Friday, 04'th Jun 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformati
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:01pm, Friday, 14'th May 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformati
Atara Biotherapeutics' (ATRA) CEO Pascal Touchon on Q1 2021 Results - Earnings Call Transcript
08:54am, Wednesday, 05'th May 2021
Atara Biotherapeutics' (ATRA) CEO Pascal Touchon on Q1 2021 Results - Earnings Call Transcript
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates
06:02pm, Tuesday, 04'th May 2021
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 7.53% and -50.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021
05:51pm, Tuesday, 27'th Apr 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformati
7 Stocks That Could Double by Summer
02:29pm, Monday, 05'th Apr 2021
These seven stocks may be risky, but they also have the potential for big returns -- as all of them are stocks that could double by summer. The post 7 Stocks That Could Double by Summer appeared first
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:35pm, Friday, 02'nd Apr 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformati
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformati
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:01pm, Friday, 05'th Mar 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformati
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2020 Results - Earnings Call Transcript
10:51pm, Monday, 01'st Mar 2021
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2020 Results - Earnings Call Transcript
NexImmune Proposes Terms For $75 Million IPO
01:18pm, Monday, 08'th Feb 2021
NexImmune Proposes Terms For $75 Million IPO
Atara Biotherapeutics to Present Data at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
04:14pm, Tuesday, 19'th Jan 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformati
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA; the “Company”), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to de
